Search Results

You are looking at 241 - 250 of 467 items for :

  • "Adjuvant therapy" x
  • Refine by Access: All x
Clear All
Full access

Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, John Chan, Kathleen R. Cho, David Cohn, Marta Ann Crispens, Nefertiti DuPont, Patricia J. Eifel, David K. Gaffney, Robert L. Giuntoli II, Ernest Han, Warner K. Huh, John R. Lurain III, Lainie Martin, Mark A. Morgan, David Mutch, Steven W. Remmenga, R. Kevin Reynolds, William Small Jr, Nelson Teng, Todd Tillmanns, Fidel A. Valea, Nicole R. McMillian, and Miranda Hughes

with cervical cancer either as 1) definitive therapy for those with locally advanced disease or for those who are poor surgical candidates, or 2) adjuvant therapy after radical hysterectomy for those who have one or more pathologic risk factors (eg

Full access

Christine M. Coticchia, Jiang Yang, and Marsha A. Moses

Group experience . J Clin Oncol 1991 ; 9 : 1138 – 1150 . 6. Young RC Walton LA Ellenberg SS . Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials . N Engl J Med 1990 ; 322

Full access

Harry T. Whelan

children treated in the CCG-945 study. No evidence was seen that temozolomide given during radiotherapy and as an adjuvant therapy resulted in improved event-free survival compared with that found in CCG-945. 4 In addition, temozolomide failed to improve

Full access

Masumi Ueda, Renato Martins, Paul C. Hendrie, Terry McDonnell, Jennie R. Crews, Tracy L. Wong, Brittany McCreery, Barbara Jagels, Aaron Crane, David R. Byrd, Steven A. Pergam, Nancy E. Davidson, Catherine Liu, and F. Marc Stewart

patients, adjuvant therapy with curative intent likely should proceed, despite the threat of COVID-19 infection during treatment. For patients with metastatic disease, treatment delays may lead to worsening performance status and loss of the window to treat

Full access

Stanley J. Miller, Murad Alam, James S. Andersen, Daniel Berg, Christopher K. Bichakjian, Glen M. Bowen, Richard T. Cheney, L. Frank Glass, Roy C. Grekin, Alan L. Ho, Anne Kessinger, Nanette Liegeois, Daniel D. Lydiatt, Jeff Michalski, William H. Morrison, Kishwer S. Nehal, Kelly C. Nelson, Paul Nghiem, Thomas Olencki, Clifford S. Perlis, Ashok R. Shaha, Malika Tuli, Marshall M. Urist, Linda C. Wang, and John A. Zic

with cytogenetics may be useful before initiating imatinib therapy. Radiation has occasionally been used as a primary therapeutic modality for DFSP, 35 but it is more commonly used as adjuvant therapy after surgery. 36 – 38 Postoperative radiation

Full access

Muhammed Aasim Yusuf, Vinay Kumar Kapoor, Refaat Refaat Kamel, Ather Kazmi, Najam Uddin, Nehal Masood, and Abdulmajeed Al-Abdulkareem

hepatocellular carcinoma . Liver Transpl 2005 ; 11 : 1086 – 1092 . 14. Llovet JM Mas X Aponte JJ . Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation . Gut 2002 ; 50 : 123 – 128

Full access

Joshua B. Brown, Reetesh K. Pai, Melissa A. Burgess, Jennifer Chennat, and Amer H. Zureikat

for borderline resectable GIST . J Natl Compr Canc Netw 2012 ; 10 : 1477 – 1482 ; quiz 1482 . 6. Corless CL Ballman KV Antonescu CR . Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected

Full access

Matt Brow, J. Russell Hoverman, Debra Patt, Bill Herman, Diana Verrilli, Jody Garey, and Roy Beveridge

support (and your adopted pathway for any given instance) when it really matters—at the point of decision—can be expensive. Agreement on common definitions can also be difficult, even for elements as simple as what constitutes third-line or adjuvant

Full access

Presenter: Margaret A. Tempero

with adjuvant therapy in the setting of resected pancreatic adenocarcinoma. Although there was an effort to try to improve median OS, it wasn’t until we got to…gemcitabine and capecitabine that we were beginning to see some improvement,” Dr. Tempero

Full access

Presenter: Thomas W. Flaig

, preferred regimens in this setting are enfortumab vedotin and erdafitinib. 3 According to Dr. Flaig, the NCCN Guidelines also provide recommendations for adjuvant therapy. “In the past, we have simply [considered] chemotherapy if patients had not received